ITRM
Companies
NASDAQ
Iterum Therapeutics plc
Health Care
$1.00
-$0.78 (-44.06%)
Price Chart
Overview
About ITRM
Iterum Therapeutics PLC is a clinical-stage pharmaceutical company. The company is engaged in developing and commercializing sulopenem to be the first and only oral and intravenous branded penem available globally. Its sulopenem program has the potential to offer a solution to the problem of antibiotic resistance and the toxicity limitations of existing agents. The company operates as a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.
Market Cap
$22.8M
Volume
717.7K
Avg. Volume
551.6K
P/E Ratio
-1.4939393
Dividend Yield
0.00%
Employees
18.0
Company Information
Risk & Correlation Analysis
Market Correlation
1.17
Moderate Correlation
Volatility
High (1.00)
Relative to market
Macro Factor Sensitivities
Interest Rates
Medium Sensitivity
Inflation
High Sensitivity
GDP Growth
High Sensitivity
Liquidity
Medium Sensitivity
Commodity Prices
Medium Sensitivity
Credit Quality
High Sensitivity
Portfolio Impact
Forecasts & Predictions
1-Month Target
$XXX.XX
+X.X% Potential
3-Month Target
$XXX.XX
+X.X% Potential
12-Month Target
$XXX.XX
+X.X% Potential
Technical Analysis
Based on technical indicators and chart patterns, ITRM shows...
AI Sentiment Analysis
Market sentiment analysis indicates...
Key Statistics
Market Cap$22.8M
Volume717.7K
P/E Ratio-1.49
Dividend Yield0.00%
Important Dates
Next Dividend
Next Earnings
May 13, 2025Related Securities
Pricing info last updated June 18, 2025 (after market close)Other info last updated April 2, 2025